Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rupatadine Fumarate in Allergic Rhinitis
NCT06709092Recruiting
- Start
- Mar 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of rupatadine in allergic rhinitis (AR). Primary endpoints: Rhinoconjunctivitis Quality of Life Questionnaire at 14 days, Visual Analogue Scale at 14 days and 3 more. Started Mar 2024; status: recruiting.
02
Drugs
rupatadine
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT06709092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06709092.